Biohaven Showcases Positive Data On Rimegepant, Oral Cgrp Receptor Antagonist, With 16 Presentations At 2019 American Headache Society (ahs) Annual Scientific Meeting Demonstrating Efficacy In Multiple Patient Types And Long-term Safety

by prnewswire.com posted 1year ago 222 views
NEW HAVEN, Conn., July 11, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced it will present 16 scientific presentations (oral and poster) highlighting new efficacy and safety data for rimegepant from Biohaven's robust clinical development...

In this article